( September 22, 2026, 22:31 GMT | Official Statement) -- MLex Summary: Florida Attorney General James Uthmeier announced a lawsuit against the three manufacturers of insulin — Eli Lilly, Novo Nordisk, and Sanofi— the major three pharmacy benefit managers —CVS Caremark, Express Scripts, and OptumRx — and rebate aggregators Zinc, Ascent, and Emisar. The complaint alleges the companies inflated published list prices for insulin and related diabetes drugs and paid rebates and fees to the PBMs in exchange for preferred formulary placement, so that both sides profited when the sticker price rose. “These companies told Florida families they were working to make insulin affordable,” Uthmeier said. “Instead, they inflated the sticker price of a medicine people cannot live without and left Florida patients to pay it."Statement follows in full. Also see attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.